1. $AMRN vs. $ENTA vs. $INFI vs. $HPTX Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=AMRN|ENTA|INFI|HPTX|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  2. $AMRN vs. $SPPI vs. $ENTA vs. $HPTX Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=AMRN|SPPI|ENTA|HPTX|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  3. $MNTA vs. $AEGR vs. $HPTX vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=MNTA|AEGR|HPTX|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  4. $GALE vs. $ENTA vs. $HPTX vs. $SPPI Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=GALE|ENTA|HPTX|SPPI|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  5. $FOLD vs. $INFI vs. $HPTX vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=FOLD|INFI|HPTX|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  6. Slingshot Bearish http://www.dailystockplays.com/Slingshot-Bearish-2015-03-29.html $DAL $KITE $HALO $BCRX $ILMN $BAH $GEVA $ACOR $SWIR $DLB $CARA $BOBE $ENTA $CMRX $MELI $MKTO $QSII

  7. $ENTA Underpriced with brilliant growth potential, in a healthy position. Infographic: http://simplywall.st/NasdaqGS:ENTA/enanta-pharmaceuticals

  8. $EXEL vs. $HPTX vs. $ENTA vs. $AEGR Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=EXEL|HPTX|ENTA|AEGR|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  9. $GALE vs. $MDXG vs. $ENTA vs. $HPTX Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=GALE|MDXG|ENTA|HPTX|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  10. $FOLD vs. $AEGR vs. $INFI vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=FOLD|AEGR|INFI|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  11. $FOLD vs. $HPTX vs. $ENTA vs. $AEGR Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=FOLD|HPTX|ENTA|AEGR|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  12. $GALE vs. $MDXG vs. $SPPI vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=GALE|MDXG|SPPI|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  13. $AMRN vs. $INFI vs. $HPTX vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=AMRN|INFI|HPTX|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  14. Some stocks that drop aren t shorts, other stocks that drop are. $ENTA is one that should ve definitely been shorted

  15. $EXEL vs. $HPTX vs. $INFI vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=EXEL|HPTX|INFI|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  16. $ENTA Unloved with splendid growth potential, in a healthy position. Infographic: http://simplywall.st/NasdaqGS:ENTA/enanta-pharmaceuticals

  17. $GALE vs. $HPTX vs. $SPPI vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=GALE|HPTX|SPPI|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  18. $AMRN vs. $HPTX vs. $SPPI vs. $ENTA Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=AMRN|HPTX|SPPI|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  19. $AMRN vs. $SPPI vs. $ENTA vs. $INFI Compared Across 9 Critical Measures http://litedev.capitalmarketlabs.com/cmld3b/tt.php?tickers=AMRN|SPPI|ENTA|INFI|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  20. $MNTA vs. $AEGR vs. $ENTA Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=MNTA|AEGR|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  21. $GILD Harvoni TRx 9,932 NRx 4,430 Sovaldi TRx 2,063 NRx 834 Viekira TRx 766 NRx 428 $ABBV got 8.1% market share of new scripts NRx. $ENTA

  22. $MNTA vs. $HPTX vs. $ENTA Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=MNTA|HPTX|ENTA|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  23. $MNTA vs. $ENTA vs. $INFI Compared Across 9 Critical Measures http://lite.capitalmarketlabs.com/cmld3b/tt.php?tickers=MNTA|ENTA|INFI|&metrics=Revenue+(TTM+US$+Millions)|Net+Income+(TTM+US$+Millions)|Revenue/Number+of+Employees+(TTM+US$+Millions)|Gross+Margin+%|Net+Income+Margin+%|Research+and+Development+Expense/Operating+Expense|Revenue+TTM,+1-Year+Growth+%|Net+Income+TTM,+1-Year+Growth+%|Price+to+Sales+(at+Quarter+End)

  24. Scan results - New 52 Week Low today: $SNDK $APOL $TSU $VIV $SINA $TDW $DV $MAT $ENTA $SCHN ... http://swingtradebot.com/events/4/equities?selected_date=2015-03-26

  25. Watch List for 3-27-2015 : $ENTA $VNDA $PVA $PDS $AKS $SPXU $SQQQ $PES $RRC $BAS